



The Interaction of Mastalgia with Depression and Quality of Life in Turkish Women

Türk Kadınlarında Yaşam Kalitesi ve Depresyon ile Mastaljinin Etkileşimi

Mastaljinin Türk Kadınlarında Yaşam Kalitesi Üzerine Etkisi / Mastalgia, Quality of Life in Turkish Women

Mehmet Ali Eryılmaz¹, Celalettin Eroglu², Kemal Arslan³, Yavuz Selvi⁴, Seher Cevcik⁵

¹Clinic of General Surgery and Early Diagnosis, Screen and Education Center of Cancer, Konya Education and Research Hospital, Konya,

²Erciyes University, School of Medicine, Department of Radiation Oncology, Kayseri, ³Konya Education and Research Hospital, Clinic of General Surgery, Konya,

⁴Konya, Education and Research Hospital, Clinic of Psychiatry, Konya, ⁵Early Diagnosis, Screen and Education Center of Cancer, Konya, Turkey

Özet

Amaç: Yaşam kalitesi ve depresyonun şiddeti ile mastaljinin etkileşimini değerlendirmeyi amaçladık. **Gereç ve Yöntem:** Bu çalışma, Ekim 2007 ile Haziran 2008 tarihleri arasında Konya KETEM' e başvuran, mastalji etyolojisi olabilecek organik bir patolojisi olmayan, meme kanseri taraması yapılan 105 kadın üzerinde yapıldı. Ağrının şiddeti, depresyon ve yaşam kalitesi sırasıyla Vizüel Analog Skala (VAS), Beck Depresyon Ölçeği (BDÖ) ve Short Form-36 (SF-36) testleriyle değerlendirildi. **Bulgular:** VAS ortalaması 5 (1-10), BDÖ ortalaması 17 (2-41) idi. Hastaların 51 (%49)'i Psikiyatri Kliniğine gönderildi. Buna göre hastaların %58' i depresif, %30' u anksiyeteli ve %4' ü hem depresif hem de anksiyeteli idi. Fiziksel ve sosyal uğraşları olanlar SF-36 ölçeğinden en yüksek puanı aldı. Yaş ile fiziksel uğraşı arasında ılımlı bir negatif ilişki ($r=-0.235$, $P=0.019$ varken, yaş ile yaşam enerjisi arasında zayıf bir pozitif ilişki ($r=0.198$, $P=0.04$) vardı. BDÖ ile fiziksel aktivite arasında zayıf bir negatif ilişki ($r=-0.146$) varken, BDÖ ile mental sağlık ve mental sağlık puanı arasında iyi bir pozitif ilişki ($r=-0.563$, $r=-0.559$) vardı. VAS ile SF-36' nın arasında ılımlı bir negatif ilişki vardı. **Tartışma:** Mastalji, kadınların yaşam kalitesini negatif etkileyen psikolojik faktörler arasında göz önünde bulundurulmalıdır.

Anahtar Kelimeler

Depresyon; Mastalji; Yaşam Kalitesi; Türk Kadınları

Abstract

Aim: The interaction of mastalgia with the severity of depression and quality of life is examined. **Material and Method:** This study was performed on 105 women screened for breast cancer having no organic pathology causing mastalgia. The severity of pain, depression, and quality of life were evaluated through Visual Analogue Scale (VAS), Beck Depression Inventory (BDI), and Short Form-36 Health Survey (SF-36). **Results:** The mean VAS and BDI scores were 5 (1-10) and 17 (2-41), respectively. Of the patients, 49% (n=51) were referred to psychiatry polyclinics. Accordingly, 58% were depressive, 30% were anxious and 4% were depressive and anxious. The patients obtained the highest scores from physical and social functioning domains of SF-36. A moderate negative association was detected between age and physical function (PF) ($r=-0.235$, $p=0.01$), while there was a mild positive association between age and vitality energy ($r=0.198$, $p=0.04$). There was a mild negative association between BDI and PF ($r=-0.146$), while there were good positive associations between BDI and mental health and mental component summary scores ($r=-0.563$, $r=-0.559$). Moderate negative associations were detected between VAS and eight domains and 2 summary scores of SF-36. **Discussion:** Mastalgia negatively effected the life quality of women, psychological factors should be considered.

Keywords

Depression; Mastalgia; Quality Of Life; Turkish Women

DOI: 10.4328/JCAM.1243

Received: 05.08.2012 Accepted: 03.09.2012 Printed: 01.03.2014

J Clin Anal Med 2014;5(2): 113-8

Corresponding Author: Mehmet Ali Eryılmaz, Konya Education and Research Hospital, Clinic of General Surgery, Konya, Turkey.

T.: +90 3322236942 F.: +90 3322236182 E-Mail: mali_eryilmaz@hotmail.com

Introduction

Mastalgia (breast pain, mastodynia) defines the pain and/or sensitivity of breast tissue [1]. Mastalgia is among the most common of women applying to breast disease policlinics [2-4]. The prevalence of mastalgia is 41-79% [5-9]. Mastalgia is generally divided into two groups; cyclic (typically its severity increases with premenstrual period, relieves with the menstruation within 7 days, monthly moderate pain) and non-cyclic (the pain which is not related to menstruation and severe pain). Cyclic mastalgia is the most common type and it affects bilateral and upper outer quadrant [5-9]. Ader et al, [9]. from the population-based study found that 68% of 18-44 aged women experienced a moderate cyclic mastalgia. Non-cyclic mastalgia is the scarce type and is localized to a merely tissue, bilaterally and refers to the pain of thorax wall rather than the breast itself. Non-cyclic mastalgia effecting the women's life may be continious or intermittent [5].

Although its etiology is not fully understood, besides caffeine consumption and smoking, increased plasma fatty acid levels, increased hormone levels, acute stress and increased prolactin levels are responsible for mastalgia [9-11]. The deficiencies in endocrinologic or histologic factors directed researchers to sought psychological factors, and psychogenic factors are supported [12].

Quality of life (QOL), which can be defined as a person's perception of his/her physical and mental health, covers broad domains, including physical, psychological, economic, spiritual and social well-being [13]. The World Health Organization defines health as a state of complete physical, mental and social well-being, and not merely the absence of disease or infirmity. Being a generic criteria for measuring QOL, Short Form-36 Health Survey (SF-36) was developed by Rand Corporation in 1992 [14]. To the best of our knowledge, there are scarce studies on the evaluation of SF-36 QOL in mastalgia patients and the current study is the first one from Turkey [15]. We aimed to determine the interaction of mastalgia with sociodemographic variables, as well as the severity of pain, depression and QOL in females complaining from mastalgia with no other organic pathologies.

Material and Method

This study was conducted between December 2007 to June 2008 in Early Diagnosis Screen and Education Center in Konya Education and Research Hospital on 105 women applied to the center for breast cancer screen with complaints of mastalgia.

Patient characteristics

After taking patient history and family history and physical examination, breast ultrasonography, mammographia, or both were performed. The patients without an organic pathology causing mastalgia after physical examination, breast ultrasonography and/or mammography were included. The patients were informed about the non-organic causes of mastalgia, their informed consents were taken and they were interviewed in a private room. The authors constructed a Mastalgia Patient Data Obtaining and Follow-up Form as follows: Age, below and above 35 years; education, primary school, secondary school, high school and university; body mass index (BMI), 30 and above obese; stressed life style, yes/no; the duration of mastalgia, 12 month and above; menstruation cycle, cyclic/non-cyclic; localiza-

tion, right and left/bilateral retroareolar, upper outer quadrant, upper inner quadrant, and widespread lower quadrant; smoking habit, yes/no; daily amount of tea and coffee consumption, 0-4 glasses, 5-9 glasses, 10 glasses and above; daily chocolate and cola drink consumption, yes/no, regular physical activity, yes/no; menopausal status, premenopausal/ postmenopausal; wearing proper clothes and bra, yes/no. The patients were screened through their status (Bilaretal mammary USG examination was done to patients under the of 40 and bilateral MG besides bilateral mammary USG examination was done to patients over the age of 40).

Short Form 36 Health Survey (SF-36)

SF-36 was constructed to survey the health status in the Medical Outcomes Study. The SF-36 was designed for use in clinical practice and research, health policy evaluations, and general population surveys. Its conceptual model was originally established in the United States, but the International Quality of Life Assessment (IQOLA) project has demonstrated its validity for the European population [16]. The reliability and the validity for the Turkish population of the scale was carried out by Pinar [17]. SF-36 Health Survey contains 36 items that are scored in eight scales: physical functioning (PF), role limitations due to physical health problems (RP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). It also includes a single item that provides an indication of perceived change in health. For each scale, a score ranging from 0 (the worst measured health) to 100 (the best measured health[14]. Additionally, scores were calculated for the physical health (PCS) and mental health (MCS) components of health-related quality of life. A standardized algorithm was used to calculate the scores for eight domains and two dimensions of the SF-36 were transformed to norm-based scores with a mean of 50 and a Standard deviation of 10. Chronbach's α was computed to assess internal consistency reliability, 0.64-0.85 in patients for all eight domains.

Beck Depression Inventory (BDI)

In the current study, BDI prepared by Beck et al [18]. was used. BDI measures the physical, emotional, cognitive and motivational symptoms. The aim of the inventory is not to diagnose depression, but to determine the objective symptoms of depression. Its validity and reliability for Turkish population have been tested by Hisli [19]. The BDI includes 21 descriptive statements regarding depressive symptoms frequently reported by individuals. Each of the items contain a 4-point severity rating scale. The scoring algorithm defines scores of 0-17 points as indicating no-to mild depression; 18-24 points as indicating moderate depression; and 25-63 points as indicating major depression [34]. The patients having scores 18 and above were referred to the psychiatry clinics in the current study. Their diagnosis in the psychiatry clinics were recorded.

Two groups were constructed according to the reference to psychiatry clinics (BDI scores ≥ 18 and ≤ 17) and they were compared for patient characteristics, SF-36 QOL with 8 dimensions and VAS.

Visual Analogue Scale (VAS)

VAS is a simple and frequently used method for the assessment of variations in intensity of pain. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line (analogue) between two end-points. VAS was used to assess the severity of pain for the last 4 weeks. Patients were requested to mark a point from a 10cm long vertical line. In the scale 0: no pain, as the severity of pain increases, the numbers also increase, and 10: worst pain imaginable.

Anthropometric indices

Weights were measured to 0.1 kg using a standard beam balance using a Tefal Ultraslim (France) accuracy in minimal (bare-foot and light clothing) underclothes. Height was determined to the nearest 1mm with portable stadiometers. The portable scales and stadiometers were calibrated daily. The BMI was calculated according to the formula weight (kg)/ height (m)².

Statistical analysis

The data were analysed using the SPSS statistical package program version 15.0 (SPSS Inc, Chicago, IL, USA). Descriptive statistics included percentages, standart deviations, means and median. Chi-square test was used to compare the qualitative variables. Depending on the type of the variables, t, r, and F analyses were performed if it did not apply to normal distribution, the Kruskal-Wallis test and Mann Whitney-U tests were also employed. Tukey (post-hoc), one of multi-comparative tests, and/or Dunn's test were applied in order to determine which group the difference originated from. Pearson correlation co-efficient was calculated in assessing the relationship between the variables. Multiple linear regression analysis was performed. The minimum acceptable level of significance was set at p<0.05.

Results

The patient characteristics were given in Table 1. The median age was 36 (18-65) years. The most common characteristics were; 77% (n=87) were primary school graduates, 90% (n=94) were in postmenopausal period, 60% (n=63) have cyclic mastalgia, 79% (n=83) have a normal body size, 41% (n=43) have bilateral mastalgia, 32% (n=34) have mastalgia in the left breast, 28% (n=29) have mastalgia in upper outer quadrant, 82% (n=86) were non-smokers, 42% (n=44) were consuming 5-9 glasses of tea-coffee daily, 95% (n=100) regular cola drinkers, 83% (n=87) were irregular chocolate consumers, 87% (n=91) were performing irregular physical activity, and 77% (n=87) were wearing proper bras.

Of the 6 from 8 domains of SF-36 QOL scale were below 50 points (RF 49.29±38.02, pain 47.57±17.72, GH 45.58±19.53, VT 44.71±19.28, RE 43.17±35.12, MH 49.41±16.40), 2 were above 50 points (PF 60.14±21.27 and SF 59.29±21.92) and both of the summary scores were below 50 points (PCS 39.94±7.24 and MCS 39.14±9.12) (Table 2, Figure 1). Mean BDI scores were 18.13±8.10 (moderate depression) and VAS scores 4.77±1.85 (below 5 points), respectively (Table 2, Figure 1).

In Table 3, the interaction of SF-36 (with 8 domains and 2 summaries) with age, duration of mastalgia, BMI, BDI, and VAS is seen. There was a negative moderate correlation between age

Table 1. Patient characteristics

Characteristics		n (%)
Age (year) (median)		36 (18-65)*
Duration of mastalgia (month) (median)		12 (1-240)*
Education status	Primary school	87 (77%)
	Secondary school	7 (7%)
	High school	13 (12%)
	University	4 (4%)
Menopausal status	Premenopausal	94 (90%)
	Postmenopausal	11 (10%)
Menstruation cycle type	Cyclic	63 (60%)
	Non-cyclic	42 (40%)
Body size	Normal	83 (79%)
	Obese	22 (21%)
Stressed life-style	Yes	81 (77%)
	No	24 (23%)
Mastalgia	Left breast	34 (32%)
	Right breast	28 (27%)
	Left-right	43 (41%)
Localization of mastalgia	Upper outer quadrant	29 (28%)
	Lower inner quadrant	4 (4%)
	Upper inner quadrant	14 (13%)
	Lower outer quadrant	22 (21%)
	Retroareolar	7 (7%)
	Widespread	21 (20%)
Smoking habit	Yes	17 (16%)
	No	86 (82%)
Daily tea-coffee consumption	0-4 glasses	35 (33%)
	5-9 glasses	44 (42%)
	10 glasses	26 (25%)
Daily cola drink consumption	Yes	5 (5%)
	No	100 (95%)
Daily chocolate consumption	Yes	18 (17%)
	No	87 (83%)
Regular physical activity	Yes	14 (13%)
	No	91 (87%)
Wearing proper clothes	Yes	13 (12%)
	No	92 (88%)
Wearing proper bra	Yes	24 (23%)
	No	81 (77%)

* (Min-Max)




Figure 1. Eight domains and 2 summary scores of SF-36.

Table 2. Mean scores of patients from SF-36 (with 8 domains), BDI, and VAS

Variables	Mean ± SD	Median (Min-Max)
Physical function (PF)	60.14 ± 21.27	60 (15-100)
Role difficulty physical (RP)	49.29 ± 38.02	50 (0-100)
Pain	47.57 ± 17.72	42 (12-100)
General health (GH)	45.58 ± 19.53	45 (0-92)
Vitality energy (VT)	44.71 ± 19.28	45 (0-95)
Social function (SF)	59.29 ± 21.92	62.5 (13-100)
Role difficulty emotional (RE)	43.17 ± 35.12	33.3 (0-100)
Mental health (MH)	49.41 ± 16.40	52 (8-80)
Physical Component Summary (PCS)	39.94 ± 7.24	41 (23-53)
Mental Component Summary (MCS)	39.14 ± 9.12	39 (17-57)
Beck Depression Inventory (BDI)	18.13 ± 8.10	17 (2-41)
Visual Analogue Scale (VAS)	4.77 ± 1.85	5 (1-10)

and PF ($r=-0.235$, $p=0.01$). There was a positive mild correlation between age and VT ($r=0.198$, $p=0.04$). There was no correla-

Discussion

Mastalgia may be prevalent (70%) among childbearing women. In 50% of the females referred to Breast Clinics having mastalgia complaint. Only 0.5% of the females with mastalgia have diagnosed with neoplasm. 85% of the females do not take a special treatment, while 15% were seriously affected and take medications. Of these patients, 2/3 have cyclic, and 1/3 have non-cyclic mastalgia [4-6;9;20]. In the current study, our results on 90% of the females were premenopausal, 60% have cyclic mastalgia, 41% have bilateral mastalgia, 28% have outer upper quadrant mastalgia, and median duration of mastalgia being 12 months is consistent with the literature. As it is not too long for follow-up, after 2 years, no neoplasm was detected. In clinical practice decreasing the intake of foods containing methyl xanthine, mainly coffee, is recommended to patients with mastalgia. However, there are a few studies determining the relationship between mastalgia and methyl xanthine consumption[21-23]. Ader et al [9], found a weak correlation be-

Table 3. The statistical analysis of the interaction between patient characteristics, SF-36, BDI, and VAS

Characteristics	PF	RP	PAIN	GH	VT	SF	RE	MH	PCS	MCS
Age (year)	-0.235**	-0.039	-0.039	0.033	0.198*	-0.065	0.025	0.145	-0.173	0.143
Duration of mastalgia (month)	-0.165	-0.059	-0.025	-0.038	0.058	0.038	0.089	-0.075	-0.147	0.008
BMI (kg/m2)	-0.177	0.036	-0.053	-0.144	0.051	-0.081	-0.012	0.065	-0.168	0.083
VAS	-0.257**	-0.349***	-0.490***	-0.319***	-0.256**	-0.249**	-0.300**	-0.330***	-0.407***	-0.327***
BDI	-0.146	-0.367***	-0.309***	-0.392***	-0.439***	-0.351***	-0.304***	-0.563***	-0.257***	-0.559***

*p<0.05, **p<0.01, ***p<0.00
PF: Physical Function, RP: Physical Role Difficulty, GH: General Health, VT: Vitality Energy, SF: Social Function, RE: Emotional Role Difficulty, MH: Mental Health, PCS: Physical Component Summary, MCS: Mental Component Summary, VAS: Visual Analogue Scale, BDI: Beck Depresyon Inventory.

tion between the duration of mastalgia and SF-36 (with 8 domains and 2 summaries). There was a negative mild correlation between BDI and PF ($r=-0.146$). There were negative moderate correlations between BDI and RF, pain, GH, VT, SF, RE, PCS ($r=-0.367$, $r=-0.309$, $r=-0.392$, $r=-0.439$, $r=-0.351$, $r=-0.304$, $r=-0.257$, respectively). There were negative moderate correlations between VAS and PF, RF, pain, GH, VT, SF, RE, MH, PCS, MCS ($r=-0.257$, $r=-0.349$, $r=-0.490$, $r=-0.319$, $r=-0.256$, $r=-0.249$, $r=-0.300$, $r=-0.330$, $r=-0.407$ and $r=-0.327$, respectively). Of the patients, 49% (n=51) (BDI scores ≥ 18) were referred to psychiatry polyclinics. According to psychiatric evaluation; 58% (n=31) of the patients were depressive, 30% (n=16) were anxious, 4% (n=4) were depressive and anxious, 4% (n=4) were depressive and somatoform disordered, 2% (n=1) were panic disordered and 2% (n=1) were obsessive compulsive disordered. According to 2 groups based on BDI scores (≥ 18 or ≤ 17) (n=51 or n=54); stressed life style and regular cola consumption were different among groups ($p=0.004$ and $p=0.006$, respectively) (Table 4). In addition to this result, GH ($p=0.008$), VT ($p=0.001$), MH ($p=0.001$), RF ($p=0.01$), pain ($p=0.05$), SF ($p=0.01$), MCS ($p=0.001$) and VAS ($p=0.04$) were significantly different among groups (Table 5). A moderate positive correlation was detected between BDI and VAS ($r=0.304$, $p=0.002$). Eight domains and 2 summary scores of SF-36 were demonstrated in Figure 1.

tween the frequency of methyl xanthine consumption and mastalgia. Gül et al [24], found no correlation between the frequency of methyl xanthine consumption and mastalgia. In the current study, 67% of the patients consuming 5 glasses/d tea-coffee finding is consistent with the weak correlation studies; and also 95% of the patients not consuming cola drinks regularly, 83% of the patients not consuming chocolate regularly, and 82% of the patients not smoking findings are consistent with the literature. In groups constructed according to BDI scores, no association was detected, except consuming cola drinks from methyl xanthine containing foods. Active breast movement on its weak suspensory ligament may contribute considerably to mastalgia. For women who exercise vigorously, a well-fitting support bra can provide substantial pain relief [25-26]. However, these results must be interpreted with caution because mastalgia shows a high rate (about 20%) of responding to placebo [27]. On the other hand, a sedentary lifestyle has been reported in up to 80% of women with mastalgia [28]. For these women, increasing physical activity levels may improve chronic pain via release of endorphins [29]. In the current study, for 77% of the women wearing improper bras and 87% of them having irregular physical activity were the causes of mastalgia. Psychosomatic causes of mastalgia is emphasized in studies and in the etiology of mastalgia psychogenic factors are also supported besides hormonal theories. In these cases, widespread anxiety disorder and major depression were more prevalent, while somatoform disorders and panic disorders were less prevalent [12].

Table 4. Comparison of patient characteristics according to BDI

Characteristics		Groups		Sta- tistical as- sess- ment
		BDI score ≥18 (n=51)	BDI score ≤17 (n=54)	
		n (%)	n (%)	p
BMI (kg/m2)	Normal	40 (48%)	43 (52%)	0.880
	Obese	11 (50%)	11 (50%)	
Stressed life style	Yes	46 (57%)	35 (43%)	0.004
	No	5 (21%)	19 (79%)	
Location of mastalgia	Unilateral (right/left)	31 (50%)	31 (50%)	0.843
	Bilateral	20 (47%)	23 (53%)	
Smoking habit	Yes	5 (30%)	12 (70%)	0.080
	No	46 (52%)	42 (48%)	
Daily tea-coffee consumption	≥ 5 glasses	16 (54%)	19 (56%)	0.812
	< 5 glasses	35 (50%)	35 (50%)	
Daily cola drink consumption	Yes	5 (100%)	0 (0%)	0.006
	No	46 (46%)	54 (54%)	
Daily chocolate consumption	Yes	6 (33%)	12 (67%)	0.245
	No	45 (52%)	42 (48%)	
Wearing unproper (tight) clothes	Yes	6 (46%)	7 (54%)	0.852
	No	45 (49%)	47 (51%)	
Wearing unproper (tight) bras	Yes	11 (46%)	13 (54%)	0.760
	No	40 (49%)	41 (51%)	
Regular physical activity	Yes	4 (29%)	10 (71%)	0.108
	No	47 (52%)	44 (48%)	
Menstruation cycle type	Cyclic	31 (49%)	32 (51%)	0.873
	Non-cyclic	20 (48%)	22 (52%)	
Menopausal status	Premenopausal	47 (50%)	47 (50%)	0.384
	Postmenopausal	4 (36%)	7 (64%)	
Education status	< High school	46 (52%)	42 (48%)	0.080
	≥ High school	5 (29%)	12 (71%)	

Although being underestimated, mastalgia is a problem which limits daily activities, effects sexual activity, and have important costs [30-31]. In women with severe mastalgia, the negative reports were mostly on sexual activity (48%), physical activity (36%), social activity (13%), and work-school performances (6%) [31]. In other studies, the association of mastalgia with psychiatric disorders as depression, anxiety, and somatoform disorders were also demonstrated [32]. Johnson et al [5]. showed a strong correlation of mastalgia with psychiatric disorders and recommended the research of depression and anxiety in mastalgia patients. In a study, a positive significant association was demonstrated with the severity of mastalgia and the depression level of the patients and inspiration had a positive effect on declining the severity of mastalgia [33]. In the current study, among patients referred to psychiatry clinics, the most prevalent disorders were depression (66%) and anxiety (34%), while the less prevalent ones were somatoform (4%), and panic disorders (2%). Also, we found that the mean BDI scores (18 points)

Table 5. Comparison of groups according to BDI scores

Characteristics	Groups		Statistical assess- ment
	BDI score ≥18	BDI score ≤17	
	Mean ± SD	Mean ± SD	p
Physical function (PF)	59.31 ± 20.85	60.93 ± 21.82	0.700
General health (GH)	40.45 ± 17.35**	50.43 ± 20.38	0.008
Vitality energy (VT)	38.63±19.82***	50.46 ± 17.02	0.001
Mental health (MH)	42.82±17.29***	55.63 ± 12.84	0.001
Physical Component Summary (PCS)	38.98 ± 6.92	40.85 ± 7.48	0.188
Mental Component Summary (MCS)	35.36 ± 8.93***	42.71 ± 7.82	0.001
Age (year)	37.04 ± 8.3	38.28 ± 9.05	0.468
Body Mass Index (BMI) (kg/m2)	26.47 ± 4.33	26.29 ± 4.39	0.838
	Median (Min-Max)	Median (Min-Max)	
Role difficulty physical (RP)	25 (0-100)	75 (0-100)	0.012
Pain	41 (12-84)	51 (12-100)	0.051
Social function (SF)	50 (13-100)	63 (25-100)	0.019
Role difficulty emotional (RE)	33 (0-100)	33 (0-100)	0.085
Visual Analogue Scale (VAS)	5 (2-10)	4 (1-8)	0.048
Duration of mastalgia (month)	12 (1-240)	12 (1-180)	0.221

*p<0.05, **p<0.01, ***p<0.001

reflected moderate depression and 77% of Turkish women had stressed lifestyles. A negative significant correlation was detected between BDI and GH, VT, MH, RF, pain, SF, MSS and as the BDI scores increased (more depressed) the patients were less active in daily routine. In addition to these results, our positive significant association between BDI and VAS finding is consistent with the current literature. The severity of mastalgia was also related to the level of depression [33].

SF-36 QOL scale is a multi-dimensional and comprehensive instrument composed of 8 domains and 2 summary scores [14]. Velanovich et al [15], found low scores for 3 subdomains of 8 domains in fibrocystic/mastalgia patients besides other diseases. In the current study, as we detected 6 dimensions of 8 domains and 2 component summaries below 50 points (2 domains below 50 points while very near to 50 points), a positive significant association between BDI and VAS, while negative significant associations between VAS and 8 domains of SF-36 and 2 component summaries all pointed out that mastalgia negatively effected the QOL in Turkish women.

In conclusion, as the non-organic mastalgia effect the QOL in Turkish women negatively, it must not be underestimated and psychological factors should also be evaluated, and a multi-disciplinary approach may be adopted.

Competing interests

The authors declare that they have no competing interests.

References

1. Srivastavaa A, Mansela RE, Arvinda N, Prasadb K, Dharc A Chabraa. Evidence-based management of mastalgia: A meta-analysis of randomised trials. The Breast 2007;16(5):503-12.
2. Davies EL, Gateley CA, Miers M, Mansel RE. The long-term course of mastalgia. J R Soc Med 1998;91(9):462-4.

3. Carmichaela AR, Bashayana O, Nightingale P. Objective analyses of mastalgia in breast clinics: Is breast pain questionnaire a useful tool in a busy breast clinic? *The Breast* 2006;15(4):498–502.
4. Millet AV, Dirbas FM. Clinical management of breast pain: a review. *Obstet Gynecol Surv* 2002;57(7):451–61.
5. Johnson KM, Bradley KA, Bush K, Gardella C, Dobie DJ, Laya MB. Frequency of mastalgia among women veterans. Association with psychiatric conditions and unexplained pain syndromes. *J Gen Intern Med* 2006;21 (Suppl 3):70–5.
6. Boyle CA, Berkowitz GS, Kelsey JL. Epidemiology of premenstrual symptoms. *Am J Public Health* 1987;77(3):349–50.
7. Leinster SJ, Whitehouse GH, Walsh PV. Cyclical mastalgia: clinical and mammographic observations in a screened population. *Br J Surg* 1987;74(3):220–2.
8. Deschamps M, Band PR, Coldman AJ. Clinical determinants of mammographic dysplasia patterns. *Cancer Detect Prev* 1996;20(6):610–9.
9. Ader DN, South-Paul J, Adera T, Deuster PA. Cyclical mastalgia: prevalence and associated health and behavioral factors. *J Psychosom Obstet Gynaecol* 2001;22(2):71–6.
10. Gateley CA, Maddox PR, Pritchard GA, Sheridan W, Harrison BJ, Pye JK, et al. Plasma fatty acid profiles in benign breast disorders. *Br J Surg* 1992;79(5): 407–9.
11. Ecochard R, Marret H, Rabilloud M, Boehringer H, Mathieu C, Guerin JF. Gonadotropin level abnormalities in women with cyclic mastalgia. *Eur J Obstet Gynecol Reprod Biol* 2001;94(1):92–6.
12. Colegrave S, Holcombe C, Salmon P. Psychological characteristics of women presenting with breast pain. *J Psychosom Res* 2001;50(6):303–7.
13. Wong E, Cronin L, Griffl L, Irvine EJ, Guyatt GH. Problems of HROL assessment: How much is too much? *J Clin Epidemiol* 2001;54(11):1081–5.
14. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473–83.
15. Velanovich V. Experience with a generic quality of life instrument in a general surgical practice. *Int J Surg Invest* 2000;1(5):447–52.
16. Alonso J, Ferrer M, Gandek B, Ware JE Jr, Aaronson NK, Mosconi P, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. *Qual Life Res* 2004;13(2):283–98.
17. Pinar R. SF-36 yaşam kalitesi ölçeği ve kullanımı, sağlık araştırmalarında yaşam kalitesi kavramı. *Sendrom* 1996;3(2):109–13.
18. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473–83.
19. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961;4:561–71.
20. Hisli N. Beck depresyon envanterinin üniversite öğrencileri için geçerliliği ve güvenirliği. *Psikoloji Dergisi* 1989;7(1):3–13.
21. Klimberg SV. Etiology and management of breast pain. In: Bland KI, Copeland EM, eds. *The Breast: Comprehensive management of benign and malignant diseases*. 2nd Ed. Philadelphia: WB Saunders, 1998;p:247–60.
22. Jenkins PL, Psych MRC, Jamil N. Psychiatric illness in patients with severe treatment-resistant mastalgia. *Gen Hosp Psychiat* 1993;15(1):55–7.
23. Schairer C, Brinton LA, Hoover RN. Methylxanthines and benign breast disease. *Am J Epidemiol* 1986;124:603–7.
24. Mansel R. Breast pain: Clinical spectrum and practical management. Forbes JF, (ed). *Clinical surgery international 10: breast diseases*. Edinburgh: Churchill Livingstone. 1986;p:48–58.
25. Gul A, Kahramanoglu I, Sucakli MH. Mastalgia prevalence and effects of methylxanthine contain foods on symptoms of mastalgia. *TJOD Dergisi* 2008;5(3):207–11.
26. Holland PA, Gateley CA. Drug treatment of mastalgia: What are the opinions? *Drugs* 1994;48(5):709–16.
27. Hadi MS. Sports brassiere: Is it a solution for mastalgia? *Breast J* 2000;6(4):407–9.
28. Gateley CA, Miers M, Mansel M, Hughes LE. Drug treatments for mastalgia: 17 years experience in the Cardiff mastalgia clinic. *J R Soc Med* 1992;85(1):12–5.
29. Wetzig NR. Mastalgia. A 3-year Australian study. *Aust NZ J Surg* 1994;64(5):329–31.
30. Sullivan MD, Turner JA, Romano J. Chronic pain in primary care: Identification and management of psychosocial factors. *J Fam Pract* 1991;32(2):193–9.
31. Faiz O, Fentiman IS. Management of breast pain: *Int J Clin Pract* 2000;54(4):228–32.
32. Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample. *Am J Obstet Gynecol* 1997;177(1):126–32.
33. Jenkins PL, Jamil N, Gateley C, Mansel RE. Psychiatric illness in patients with severe treatment-resistant mastalgia. *Gen Hosp Psychiatry* 1993;15(1):55–7.
34. Cakir T, Cingi A, Fistikci N, Bez Y, Topcuoglu V, Gulluoglu BM. The role of reassurance in the management of patients with nonorganic mastalgia. *J Breast Health* 2006;2(1):96–9.